Shots:
- The EC has approved Tepkinly (epcoritamab) in combination with lenalidomide and rituximab (Tepkinly + R2) for the treatment of adults with R/R follicular lymphoma (FL)
- Approval was based on the P-III (EPCORE FL-1) trial assessing fixed-duration Tepkinly + R2 (n=243) vs SoC R2 (n=245) in pts with R/R FL following ≥1 prior line of treatment
- Trial showed Tepkinly + R2 reduced the risk of disease progression or death by 79% & demonstrated an ORR of 96% vs 81%, with a CR of 74% (n=181/243) vs 43% (n=106/245); data were published in The Lancet
Ref: Businesswire | Image: AbbVie & Genmab | Press Release
Related News: AbbVie and Genmab Report P-III (EPCORE DLBCL-4) Trial Data Results on Epcoritamab + Lenalidomide for R/R DLBCL
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
